1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Teva’s Schultz Sets Sights On The Horizon While Continuing To Face Headwinds

 
• By Dave Wallace

Teva chief Kåre Schultz has set out his vision for the company to be a world leader in generics, complex generics and biologics, even as he continues to cut staff and shut manufacturing sites as part of cost-cutting measures. In the meantime, the firm faces a “trough year” in 2019, and its profitability is continuing to suffer due to impairments including charges linked to its acquisition of Actavis in 2016.

StormBoat
Teva Is Setting Its Sights On A Brighter Future • Source: Shutterstock

Asked to set out his long-term vision for Teva, president and chief executive officer Kåre Schultz is clear. “Our vision is to be, and continue to be, leaders in generics worldwide, and to build a strong pipeline and have success in biopharmaceuticals, meaning both biosimilars and innovative biologics,” he told his audience as Teva reported its 2018 annual results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Wockhardt Confirms US Market Exit After Past Challenges

 
• By Adam Zamecnik

Following past challenges on the US market, the Indian pharma player Wockhardt will be shuttering its presence in the country due to commercial reasons.

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.

Sandoz Attacks Amgen Over US Enbrel Exclusivity

 
• By Dave Wallace

Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."

Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.

More from Business

Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By Adam Zamecnik

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab

 
• By Dave Wallace

Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.